Showing results 8 to 9 of 9
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
Phase 3, randomized, double-blind, dummy-controlled, trial of radiofrequency ablation (RFA) + lyso-thermosensitive liposomal doxorubicin (LTLD, Thermodox), for hepatocellular carcinoma (HCC) lesions 3-7 cm Proceeding/Conference:Annual Conference of the International Liver Cancer Association, ILCA 2013 | - | ||
2001 |